CMG Pharmaceutical Co., Ltd. (058820.KQ)
KRW 2600.0
(-0.95%)
KRW 2600.0
(-0.95%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 40.02 Billion KRW | 78.07% |
| 2022 | 22.48 Billion KRW | 416.12% |
| 2021 | 4.35 Billion KRW | 9.91% |
| 2020 | 3.96 Billion KRW | -62.12% |
| 2019 | 10.46 Billion KRW | 11.99% |
| 2018 | 9.34 Billion KRW | -14.27% |
| 2017 | 10.89 Billion KRW | 33.2% |
| 2016 | 8.17 Billion KRW | -1.03% |
| 2015 | 8.26 Billion KRW | -0.49% |
| 2014 | 8.3 Billion KRW | 26.8% |
| 2013 | 6.55 Billion KRW | 1449.51% |
| 2012 | 422.74 Million KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 42.45 Billion KRW | 43.51% |
| 2024 Q1 | 40.8 Billion KRW | 1.94% |
| 2023 Q3 | 37.71 Billion KRW | -1.49% |
| 2023 Q4 | 40.02 Billion KRW | 6.14% |
| 2023 FY | 51.86 Billion KRW | 83.22% |
| 2023 Q1 | 36.01 Billion KRW | 60.22% |
| 2023 Q2 | 38.28 Billion KRW | 6.3% |
| 2022 Q3 | 4.49 Billion KRW | 2.25% |
| 2022 Q2 | 4.39 Billion KRW | 1.33% |
| 2022 Q1 | 4.33 Billion KRW | -0.51% |
| 2022 Q4 | 22.48 Billion KRW | 400.66% |
| 2022 FY | 28.3 Billion USD | 95.6% |
| 2021 Q3 | 4.31 Billion KRW | 4.11% |
| 2021 FY | 14.47 Billion USD | 1.74% |
| 2021 Q2 | 4.14 Billion KRW | 2.34% |
| 2021 Q4 | 4.35 Billion KRW | 0.9% |
| 2021 Q1 | 4.05 Billion KRW | 2.24% |
| 2020 Q4 | 3.96 Billion KRW | 3.57% |
| 2020 FY | 14.22 Billion USD | 35.99% |
| 2020 Q1 | 11.92 Billion KRW | 13.96% |
| 2020 Q2 | 3.66 Billion KRW | -69.25% |
| 2020 Q3 | 3.82 Billion KRW | 4.38% |
| 2019 Q2 | 12.58 Billion KRW | 14.49% |
| 2019 Q1 | 10.98 Billion KRW | 17.65% |
| 2019 Q4 | 10.46 Billion KRW | -5.28% |
| 2019 FY | 3.42 Billion USD | 2224.56% |
| 2019 Q3 | 11.04 Billion KRW | -12.22% |
| 2018 Q3 | 11.17 Billion KRW | -1.88% |
| 2018 FY | 449.99 Million USD | 38.93% |
| 2018 Q4 | 9.34 Billion KRW | -16.43% |
| 2018 Q2 | 11.39 Billion KRW | -1.23% |
| 2018 Q1 | 11.53 Billion KRW | 5.86% |
| 2017 Q4 | 10.89 Billion KRW | 6.12% |
| 2017 FY | 323.89 Million USD | 14.94% |
| 2017 Q1 | 8.93 Billion KRW | 9.19% |
| 2017 Q2 | 8.69 Billion KRW | -2.61% |
| 2017 Q3 | 10.26 Billion KRW | 18.03% |
| 2016 Q4 | 8.17 Billion KRW | -2.03% |
| 2016 Q2 | 8.03 Billion KRW | -11.12% |
| 2016 Q1 | 9.04 Billion KRW | 9.42% |
| 2016 Q3 | 8.34 Billion KRW | 3.87% |
| 2016 FY | 281.79 Million USD | -52.81% |
| 2015 Q1 | 8.16 Billion KRW | -1.73% |
| 2015 Q4 | 8.26 Billion KRW | 18.95% |
| 2015 FY | 597.09 Million USD | 143.01% |
| 2015 Q3 | 6.94 Billion KRW | -7.77% |
| 2015 Q2 | 7.53 Billion KRW | -7.7% |
| 2014 Q3 | 7.93 Billion KRW | -0.58% |
| 2014 Q1 | 7.36 Billion KRW | 12.47% |
| 2014 FY | 245.71 Million USD | 23.33% |
| 2014 Q4 | 8.3 Billion KRW | 4.63% |
| 2014 Q2 | 7.98 Billion KRW | 8.37% |
| 2013 FY | 199.22 Million USD | -52.87% |
| 2013 Q1 | 23.01 Billion KRW | 5344.73% |
| 2013 Q2 | 6.61 Billion KRW | -71.25% |
| 2013 Q3 | 7.43 Billion KRW | 12.35% |
| 2013 Q4 | 6.55 Billion KRW | -11.91% |
| 2012 Q4 | 422.74 Million KRW | 0.0% |
| 2012 FY | 422.74 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 53.19 Billion KRW | 24.753% |
| Celltrion Pharm, Inc. | 264.97 Billion KRW | 84.893% |
| Huons Global Co., Ltd. | 407.28 Billion KRW | 90.172% |
| DongKook Pharmaceutical Co., Ltd. | 263.36 Billion KRW | 84.8% |
| Enzychem Lifesciences Corporation | 16.91 Billion KRW | -136.599% |
| Humedix Co., Ltd. | 21.91 Billion KRW | -82.663% |
| Boditech Med Inc. | 30.48 Billion KRW | -31.31% |
| EuBiologics Co., Ltd. | 67.82 Billion KRW | 40.98% |
| FutureChem Co.,Ltd | 8.91 Billion KRW | -348.825% |
| Huons Co., Ltd. | 206.87 Billion KRW | 80.65% |
| BNC Korea Co., Ltd. | 21.94 Billion KRW | -82.402% |
| AptaBio Therapeutics Inc. | 38.19 Billion KRW | -4.812% |